J&J in talks to buy Shockwave Medical, WSJ reports
Reuters
Published Mar 26, 2024 02:33PM ET
Updated Mar 26, 2024 04:01PM ET
(Reuters) -Johnson & Johnson is in talks to buy medical device maker Shockwave Medical (NASDAQ:SWAV), the Wall Street Journal reported on Tuesday, as the healthcare giant potentially looks to expand its presence in cardiovascular devices.
Shockwave, a company that makes devices to treat heart disease, has a market capitalization of around $11 billion, according to LSEG data.
A deal could be finalized in the coming weeks if talks don't fall apart and it is also possible another suitor could emerge, the report said, citing people familiar with the matter. It did not mention the value of the deal.
WSJ's is the latest media report on a potential bid for Shockwave Medical after Bloomberg News reported last year that Boston Scientific (NYSE:BSX) was weighing an offer for the heart device maker.
When contacted for comment on the WSJ report, J&J (NYSE:JNJ) and Shockwave Medical said they do not comment on rumors or speculation.
News of the talks lifted shares of Shockwave Medical up 11.5% in afternoon trade.
The company makes a device which uses shockwaves to break down calcified plaque in heart vessels, similar to how kidney stones are treated.
J&J said last year it was looking for opportunities to merge with or acquire firms that could add value to its own portfolio of cardiovascular products, adding that many of its future deals would likely be small "tuck-in" acquisitions.
In 2022, the company acquired heart pump maker Abiomed (NASDAQ:ABMD) for $16.6 billion.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.